Is it true that gut microbiota is considered as panacea in cancer therapy? |
| |
| Authors: | Amir Salek Farrokhi Narges Darabi Bahman Yousefi Rafee Habib Askandar Mansoreh Shariati Majid Eslami |
| |
| Institution: | 1. Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran;2. Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran;3. Nursing Department, Halabja Technical Institute, Sulaimani Polytechnic University, Sulaimani, Iraq;4. Faculty of Basic Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran |
| |
| Abstract: | Recent studies demonstrated that a combination of the gut microbiome has the vital effect on the efficacy of anticancer immune therapies. Regulatory effects of microbiota have been shown in different types of cancer therapies such as chemotherapy and immunotherapy. Immune-checkpoint-blocked therapies are the recent efficient cancer immunotherapy strategies. The target of immune-checkpoint blocking is cytotoxic T lymphocyte protein-4 (CTLA-4) or blockade of programmed death-1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) that they have been considered as cancer immunotherapy in recent years. In the latest studies, it have been demonstrated that several gut bacteria such as Akkermansia muciniphila, Bifidobacterium spp., Faecalibacterium spp., and Bacteroides fragilis have the regulatory effects on PD-1, PD-L1, and CTLA-4 blocked anticancer therapy outcome. |
| |
| Keywords: | cancer therapy cytotoxic T lymphocyte protein-4 microbiome programmed death-1 |
|
|
